Notably, upregulation of OXPHOS proteins occurs in melanoma patients progressing on BRAF and MEK targeted therapy14, and patient response to BRAFi correlates with glycolytic response as assessed by FDG-PET imaging11, suggesting that inactivation of adaptive translational reprogramming may mitigate therapy-induced metabolic plasticity and improve targeted therapy response in melanoma patients. Here, BRAF is linked to melanoma.